Charles River(CRL) - 2025 Q4 - Earnings Call Transcript

Financial Data and Key Metrics Changes - The company reported revenue of $994.2 million in Q4 2025, a 2.6% decline on an organic basis from the previous year, with full-year revenue of $4.02 billion, reflecting a 1.6% organic revenue decrease [12][14] - Earnings per share were $2.39 in Q4 2025, a decrease of 10.2% from $2.66 in Q4 2024, while full-year earnings per share were nearly flat at $10.28 compared to $10.32 in 2024 [14] - The operating margin decreased by 100 basis points year-over-year to 18.1% in Q4, while the full-year operating margin declined by just 10 basis points to 19.8% [13][14] Business Segment Data and Key Metrics Changes - DSA revenue in Q4 was $591.6 million, a decrease of 3.3% on an organic basis, with a full-year decline of 2.6% [15] - RMS revenue in Q4 was $206.3 million, a decrease of 0.9% on an organic basis, while full-year RMS revenue increased by 1.2% [19] - Manufacturing solutions revenue was $196.4 million for Q4, a decrease of 2.1% on an organic basis, with full-year revenue declining by 1.6% [21][22] Market Data and Key Metrics Changes - The DSA net book-to-bill improved to 1.1 times in Q4, driven by small and mid-sized biotech clients, with a backlog of $1.86 billion at year-end [6][17] - The biotech funding environment saw a record level of $28 billion in Q4, contributing to a steady increase in DSA net bookings [6][12] - Sales to global biopharma clients rebounded in Q4, while small and mid-sized biotech clients experienced a modest decline [12][13] Company Strategy and Development Direction - The company is focused on strategic acquisitions to strengthen its portfolio, including the acquisition of K.F. Cambodia and PathoQuest, aimed at enhancing operational efficiency and securing supply chains [8][9] - The company plans to continue evaluating additional M&A opportunities to support clients in drug development [9][10] - The emphasis on NAMs (new approach methodologies) and AI as enabling technologies is part of the long-term strategy to enhance scientific capabilities [10][66] Management's Comments on Operating Environment and Future Outlook - Management expressed cautious optimism regarding favorable DSA demand trends continuing into 2026, anticipating a return to organic revenue growth in the second half of the year [6][30] - The company expects operating margin improvement driven by the acquisition of K.F. Cambodia, with projected non-GAAP earnings per share growth of approximately 4%-9% for 2026 [28][32] - Management acknowledged challenges in the first quarter of 2026, including higher NHP sourcing costs and stock compensation expenses due to the CEO transition [43][44] Other Important Information - The company plans to generate at least $100 million in incremental cost savings in 2026, building on previous restructuring initiatives [33] - The anticipated decrease in the non-GAAP tax rate for 2026 is expected to be in the range of 22%-23% [46] - The company is focused on maintaining a disciplined approach to capital deployment, with a projected free cash flow of $375 million-$400 million for 2026 [48][49] Q&A Session Summary Question: Dynamics between RMS and DSA regarding NHPs - Management clarified that RMS is facing headwinds from lower NHP volumes due to timing, while DSA is experiencing higher sourcing costs due to increased demand for NHP studies [54][55] Question: DSA cancellations and their impact - Management indicated that cancellations and slippage are normal elements of the business, with current levels consistent with expectations and manageable due to a strong backlog [74][75]